Breast cancer · 6 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
CP-EC and Pembrolizumab Variant #01 | TNBC | R 87 755 | 21d | — | — | ~8 | ~R 678 968 indirect | — |
CP-AC and Pembrolizumab Variant #01 | TNBC | R 86 199 | 21d | — | — | ~8 | ~R 672 744 indirect | — |
nP-ddAC and Atezolizumab Variant #01 | TNBC | R 62 757 | 14d | — | — | 10 | R 462 512 PFS proxy | 1 |
nP-ddAC Variant #01 | TNBC | R 40 878 | 14d | — | — | 6 | R 243 730 PFS proxy | 1 |
CP-EC Variant #01 | TNBC | R 5 768 | 21d | — | — | ~4 | ~R 23 071 indirect | — |
CP-AC Variant #01 | TNBC | R 4 212 | 21d | — | — | ~4 | ~R 16 846 indirect | — |
6 of 6 regimens shown